硫酸镁联合拉贝洛尔、硝苯地平控释片治疗妊娠合并高血压的效果评价
|
摘要
目的探讨硫酸镁联合拉贝洛尔、硝苯地平控释片治疗妊娠合并高血压的效果。方法选择2017年6月～2018年12月期间我院收治的妊娠合并高血压患者中随机抽取60例为研究对象,并将其随机分为两组,对照组患者接受硫酸镁+拉贝洛尔进行治疗,观察组患者予以硫酸镁+拉贝洛尔+硝苯地平控释片进行治疗。通过观察两组患者临床治疗有效率及治疗前后血压变化效果等方面的差异,判定二者的治疗效果。结果观察组患者治疗有效率高于对照组(93.33%vs 66.67%,χ2=11.924,P=0.001)。观察组治疗后收缩压、舒张压水平显著低于对照组,且24 h蛋白尿定量水平、脐动脉阻力指数等指标改善效果均显著优于对照组,差异有统计学意义(P<0.05)。结论硫酸镁联合拉贝洛尔、硝苯地平治疗妊娠合并高血压疗效显著,能够有效平衡患者血压水平,控制24 h尿蛋白定量,安全性高,值得推广。
Objective To investigate the effect of magnesium sulfate combined with labetalol and nifedipine controlled release tablets in the treatment of pregnancy complicated with hypertension. Methods A total of 60 patients with pregnancy complicated with hypertension admitted in our hospital from June 2017 to December 2018 were randomly divided into two groups. The control group received magnesium sulfate +labetalol. Patients in the observation group were treated with magnesium sulfate+labetalol+nifedipine controlled release tablets. The therapeutic effects of the two groups were determined by observing the difference between the clinical treatment efficiency of the two groups of patients and the effects of blood pressure changes before and after treatment. Results The effective rate of treatment in the observation group was higher than that in the control group(93.33% vs 66.67%, χ2=11.924, P=0.001). The systolic blood pressure and diastolic blood pressure levels in the observation group were significantly lower than those in the control group, and the improvement effect of 24 h proteinuria and umbilical artery resistance index in the observation group was significantly better than that of control group, and the difference was statistically significant(P<0.05). Conclusion Magnesium sulfate combined with labetalol and nifedipine is significantly effective in the treatment of pregnancy complicated with hypertension. It can effectively balance the blood pressure level of patients and control the 24-hour urine protein quantitation. It is safe and worth promoting.
Objective To investigate the effect of magnesium sulfate combined with labetalol and nifedipine controlled release tablets in the treatment of pregnancy complicated with hypertension. Methods A total of 60 patients with pregnancy complicated with hypertension admitted in our hospital from June 2017 to December 2018 were randomly divided into two groups. The control group received magnesium sulfate +labetalol. Patients in the observation group were treated with magnesium sulfate+labetalol+nifedipine controlled release tablets. The therapeutic effects of the two groups were determined by observing the difference between the clinical treatment efficiency of the two groups of patients and the effects of blood pressure changes before and after treatment. Results The effective rate of treatment in the observation group was higher than that in the control group(93.33% vs 66.67%, χ2=11.924, P=0.001). The systolic blood pressure and diastolic blood pressure levels in the observation group were significantly lower than those in the control group, and the improvement effect of 24 h proteinuria and umbilical artery resistance index in the observation group was significantly better than that of control group, and the difference was statistically significant(P<0.05). Conclusion Magnesium sulfate combined with labetalol and nifedipine is significantly effective in the treatment of pregnancy complicated with hypertension. It can effectively balance the blood pressure level of patients and control the 24-hour urine protein quantitation. It is safe and worth promoting.
引文
[1]张大微,王连涛,李雪莲,等.硝苯地平和拉贝洛尔治疗妊娠期高血压疾病的优劣差异[J].中国医药科学,2018,8(18):82-84,122.
[2]陈鹏,史琳,杨红梅,等.妊娠期高血压、子痫前期及子痫与孕前和孕期体质量及其他因素的相关性研究[J].实用妇产科杂志,2017,33(11):848-852.
[3]符泽美,王爱丽,裴雄越.硫酸镁联合硝苯地平或拉贝洛尔治疗妊娠高血压疗效比较[J].海南医学,2016,27(14):2346-2348.
[4]黄梦威,梅劼.妊娠期高血压疾病孕产妇转诊问题探讨[J].中国计划生育和妇产科,2018,10(4):17-20.
[5]俞晓敏,古航.高龄孕妇妊娠合并症和并发症临床分析[J].第二军医大学学报,2018,39(2):159-164.
[6]胡冬冬.硫酸镁联合拉贝洛尔硝苯地平治疗重度子痫前期72例临床疗效观察[J].中国药物与临床,2016,16(2):277-279.
[7]温洁红,胡蕾.硫酸镁联合硝苯地平及拉贝洛尔治疗子痫前期高血压的临床观察[J].岭南心血管病杂志,2015,21(4):537-538.
[8]Sharma KJ,Greene N,Kilpatrick SJ.Oral labetalol compared to oral nifedipine for postpartum hypertension:Arandomized controlled trial[J].Clinical&Experimental Hypertension Part B Hypertension in Pregnancy,2017,36(1):44-47.
[9]刘丽群.硫酸镁联合硝苯地平、拉贝洛尔治疗妊娠高血压疗效观察[J].现代诊断与治疗,2016,27(20):3842-3843.
[10]Shawkat E,Mi stry H,Chmiel C,et al.The effect of labetalol and nifedipine MR on blood pressure in women with chronic hypertension in pregnancy[J].Pregnancy Hypertension,2016,6(3):147-148.
[11]Shekhar S,Gupta N,Kirubakaran R,et al.Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy:A systematic review and meta-analysis[J].Bjog An International Journal of Obstetrics&Gynaecology,2016,123(1):40-47.
[12]杨红云.硫酸镁联合硝苯地平及拉贝洛尔治疗子痫前期高血压疗效分析[J].中国现代药物应用,2016,10(9):143-144.
[13]邹娜.试析硫酸镁联合拉贝洛尔治疗妊娠期高血压疾病的疗效[J].当代医学,2018,24(7):150-151.
[14]Webster L,Myers J,Nelson-Piercy C,et al.9 Pregnancy and chronic hypertension:Nifedipinevs labetalol as antihypertensive treatment(the panda study):Anti-hypertensive medications[J].Pregnancy Hypertension An International Journal of Womens Cardiovascular Health,2016,6(3):141.
[15]Shi DD,Yang FZ,Zhou L,et al.Oral nifedipine vs.intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia[J].Journal of Clinical Pharmacy&Therapeutics,2016,41(6):657-661.
[16]徐正芳.拉贝洛尔与硫酸镁对重症妊娠高血压患者分娩结局的影响[J].当代医学,2015,21(16):139-140.
[17]曹亚磊,邢宝恒,史丹丹.硝苯地平+拉贝洛尔治疗早期妊娠合并高血压的疗效及安全性[J].中国医药导刊,2017,19(6):605-607.
[18]Qi C,Xiao X,Zhao M,et al.7 The antihypertensives,nifedipine and labetalol prevent endothelial cell activation in response to placental extracellular vesicles released from 1st trimester placental explants that had been treated with preeclampticsera:Endothelial dysfunction,anti-[J].Pregnancy Hypertension An International Journal of Womens Cardiovascular Health,2016,6(3):140.
[2]陈鹏,史琳,杨红梅,等.妊娠期高血压、子痫前期及子痫与孕前和孕期体质量及其他因素的相关性研究[J].实用妇产科杂志,2017,33(11):848-852.
[3]符泽美,王爱丽,裴雄越.硫酸镁联合硝苯地平或拉贝洛尔治疗妊娠高血压疗效比较[J].海南医学,2016,27(14):2346-2348.
[4]黄梦威,梅劼.妊娠期高血压疾病孕产妇转诊问题探讨[J].中国计划生育和妇产科,2018,10(4):17-20.
[5]俞晓敏,古航.高龄孕妇妊娠合并症和并发症临床分析[J].第二军医大学学报,2018,39(2):159-164.
[6]胡冬冬.硫酸镁联合拉贝洛尔硝苯地平治疗重度子痫前期72例临床疗效观察[J].中国药物与临床,2016,16(2):277-279.
[7]温洁红,胡蕾.硫酸镁联合硝苯地平及拉贝洛尔治疗子痫前期高血压的临床观察[J].岭南心血管病杂志,2015,21(4):537-538.
[8]Sharma KJ,Greene N,Kilpatrick SJ.Oral labetalol compared to oral nifedipine for postpartum hypertension:Arandomized controlled trial[J].Clinical&Experimental Hypertension Part B Hypertension in Pregnancy,2017,36(1):44-47.
[9]刘丽群.硫酸镁联合硝苯地平、拉贝洛尔治疗妊娠高血压疗效观察[J].现代诊断与治疗,2016,27(20):3842-3843.
[10]Shawkat E,Mi stry H,Chmiel C,et al.The effect of labetalol and nifedipine MR on blood pressure in women with chronic hypertension in pregnancy[J].Pregnancy Hypertension,2016,6(3):147-148.
[11]Shekhar S,Gupta N,Kirubakaran R,et al.Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy:A systematic review and meta-analysis[J].Bjog An International Journal of Obstetrics&Gynaecology,2016,123(1):40-47.
[12]杨红云.硫酸镁联合硝苯地平及拉贝洛尔治疗子痫前期高血压疗效分析[J].中国现代药物应用,2016,10(9):143-144.
[13]邹娜.试析硫酸镁联合拉贝洛尔治疗妊娠期高血压疾病的疗效[J].当代医学,2018,24(7):150-151.
[14]Webster L,Myers J,Nelson-Piercy C,et al.9 Pregnancy and chronic hypertension:Nifedipinevs labetalol as antihypertensive treatment(the panda study):Anti-hypertensive medications[J].Pregnancy Hypertension An International Journal of Womens Cardiovascular Health,2016,6(3):141.
[15]Shi DD,Yang FZ,Zhou L,et al.Oral nifedipine vs.intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia[J].Journal of Clinical Pharmacy&Therapeutics,2016,41(6):657-661.
[16]徐正芳.拉贝洛尔与硫酸镁对重症妊娠高血压患者分娩结局的影响[J].当代医学,2015,21(16):139-140.
[17]曹亚磊,邢宝恒,史丹丹.硝苯地平+拉贝洛尔治疗早期妊娠合并高血压的疗效及安全性[J].中国医药导刊,2017,19(6):605-607.
[18]Qi C,Xiao X,Zhao M,et al.7 The antihypertensives,nifedipine and labetalol prevent endothelial cell activation in response to placental extracellular vesicles released from 1st trimester placental explants that had been treated with preeclampticsera:Endothelial dysfunction,anti-[J].Pregnancy Hypertension An International Journal of Womens Cardiovascular Health,2016,6(3):140.